2024
Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2017
Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States
Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Internal Medicine 2017, 177: 1613-1621. PMID: 28975270, PMCID: PMC5675744, DOI: 10.1001/jamainternmed.2017.4349.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLung cancer mortalityAge 40 yearsAntiretroviral therapyLung cancerCancer mortalityLower lung cancer mortalityIncomplete ART adherenceLung cancer deathsAge 80 yearsRisk of deathMortality risk ratioHigher overall mortalityStandard demographic dataGreater AIDSLight smokersSmoking exposureCurrent smokersFormer smokersART adherenceModerate smokersOverall mortalitySmoking habitsSmoking statusImmunodeficiency virus
2012
Home HIV testing: good news but not a game changer.
Paltiel AD, Walensky RP. Home HIV testing: good news but not a game changer. Annals Of Internal Medicine 2012, 157: 744-6. PMID: 23044643, PMCID: PMC3661188, DOI: 10.7326/0003-4819-157-10-201211200-00545.Peer-Reviewed Original Research
2009
Cost-effectiveness of Total Knee Arthroplasty in the United States: Patient Risk and Hospital Volume
Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA, Holt HL, Solomon DH, Yelin E, Paltiel AD, Katz JN. Cost-effectiveness of Total Knee Arthroplasty in the United States: Patient Risk and Hospital Volume. JAMA Internal Medicine 2009, 169: 1113-1121. PMID: 19546411, PMCID: PMC2731300, DOI: 10.1001/archinternmed.2009.136.Peer-Reviewed Original Research
2007
Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries
Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 78-90. PMID: 17589368, PMCID: PMC3570247, DOI: 10.1097/qai.0b013e31812506fd.Peer-Reviewed Original ResearchConceptsEffective HIV vaccineHIV prevalenceHIV vaccineCondom useHIV infectionRisk behaviorsFuture HIV prevalenceTotal HIV infectionsHeterosexual HIV epidemicSuccessful vaccination campaignsRisk behavior changeVaccination statusMiddle-income countriesVaccinated individualsVaccination coverageDisease stageVaccine efficacyHIV epidemicVaccination scenariosVaccination campaignHigh riskAdult populationVaccinePrevalenceInfection
2006
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals Of Internal Medicine 2006, 145: 797-806. PMID: 17146064, DOI: 10.7326/0003-4819-145-11-200612050-00004.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioDollars/QALYHIV prevalenceAnnual incidenceHIV infectionRoutine HIVAntiretroviral therapyIncremental cost-effectiveness ratioModerate HIV prevalenceUndetected HIV infectionVoluntary HIV screeningUndiagnosed HIV infectionRapid HIV testingHIV patient careHIV transmission riskOne-time screeningQuality-adjusted survivalLifetime medical costsServices Utilization SurveySecondary transmissionBase-case analysisCost-effectiveness analysisHIV screeningObservational cohortHIV testing
2005
Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness. New England Journal Of Medicine 2005, 352: 586-595. PMID: 15703423, DOI: 10.1056/nejmsa042088.Peer-Reviewed Original ResearchConceptsOne-time screeningEnzyme-linked immunosorbent assayGeneral populationHuman immunodeficiency virus (HIV) infectionRoutine HIV counselingEffective antiretroviral therapyImmunodeficiency virus infectionLow-risk populationHigh-risk populationQuality-adjusted survivalCost-effectiveness ratioU.S. general populationAverage survival timeCDC thresholdAntiretroviral therapyHIV screeningHIV antibodiesObservational cohortHIV counselingClinical trialsCost-effectiveness groundsVirus infectionEarly diagnosisVoluntary screeningSurvival time
2004
A Single Measure of FEV1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up
Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, Fuhlbrigge AL. A Single Measure of FEV1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up. CHEST Journal 2004, 126: 1875-1882. PMID: 15596687, DOI: 10.1378/chest.126.6.1875.Peer-Reviewed Original ResearchConceptsSubsequent asthma attacksAsthma attacksAsthma severityUS cohortNetherlands cohortUse of spirometryClinical practice guidelinesLongitudinal cohort studyAssociated shortnessObjective measuresAsthma careAsthma outcomesCohort studyCurrent smokingIndependent predictorsAdverse outcomesPractice guidelinesCohortLittle dataFEV1RiskSubjectsSeverityOutcomesSpirometry
2002
Task Force #2—the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. Task Force #2—the cost of prevention: can we afford it? Can we afford not to do it? Journal Of The American College Of Cardiology 2002, 40: 603-615. PMID: 12204490, DOI: 10.1016/s0735-1097(02)02083-1.Peer-Reviewed Original Research
2001
Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts
Yazdanpanah Y, Chêne G, Losina E, Goldie S, Merchadou L, Alfandari S, Seage G, Sullivan L, Marimoutou C, Paltiel A, Salamon R, Mouton Y, Freedberg K. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. International Journal Of Epidemiology 2001, 30: 864-871. PMID: 11511618, DOI: 10.1093/ije/30.4.864.Peer-Reviewed Original ResearchConceptsPneumocystis carinii pneumoniaPrimary opportunistic infectionCommon opportunistic infectionOpportunistic infectionsCarinii pneumoniaToxoplasmic encephalitisCytomegalovirus infectionIncidence rateGroupe d'Epidémiologie Clinique du SIDAAIDS Reference CenterCD4 lymphocyte declineIncidence of HIVHuman immunodeficiency virusAbsence of prophylaxisHIV risk behaviorsHigh incidence rateHospital-based information systemCandida esophagitisCount declineImmunodeficiency virusLymphocyte declineAntiretroviral drugsClinical guidelinesSpecific infectionsClinical cohortFEV1 is associated with risk of asthma attacks in a pediatric population
Fuhlbrigge A, Kitch B, Paltiel A, Kuntz K, Neumann P, Dockery D, Weiss S. FEV1 is associated with risk of asthma attacks in a pediatric population. Journal Of Allergy And Clinical Immunology 2001, 107: 61-67. PMID: 11149992, DOI: 10.1067/mai.2001.111590.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAsthmaChildCohort StudiesForced Expiratory VolumeHumansRetrospective StudiesRisk FactorsConceptsNational Asthma EducationAsthma attacksAsthma outcomesAsthma educationOdds ratioAdverse asthma outcomesPrevention Program recommendationsSubsequent asthma attacksSelf-report groupSurvey 1 yearRespiratory QuestionnairePulmonary functionRetrospective cohortAsthma severityIndependent predictorsLung functionPediatric populationLung healthProportion of individualsPrevention programsStandard questionnaireMultivariate modelAssessment of riskStrong associationLongitudinal study
1998
The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections
Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 1998, 279: 130-136. PMID: 9440663, DOI: 10.1001/jama.279.2.130.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAnti-Infective AgentsCD4 Lymphocyte CountChemopreventionCost-Benefit AnalysisCytomegalovirus InfectionsData CollectionHealth Care CostsHumansLife ExpectancyMarkov ChainsModels, TheoreticalMycobacterium avium-intracellulare InfectionMycosesPneumonia, PneumocystisQuality-Adjusted Life YearsRisk FactorsToxoplasmosisUnited StatesConceptsPneumocystis carinii pneumoniaCD4 cell countQuality-adjusted life expectancyOpportunistic infectionsCell countLife expectancyAdvanced human immunodeficiency virus diseaseAverage total lifetime costsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex infectionMulticenter AIDS Cohort StudyIncremental cost-effectiveness ratioHIV patient careCost of prophylaxisCost-effective prophylaxisDirect medical costsAIDS Cohort StudyLifetime direct medical costsLong-term survivalCost-effectiveness ratioServices Utilization SurveyMarkov simulation modelTotal lifetime costsCytomegalovirus diseasePreventing AIDS